MitoChem Therapeutics

MitoChem Therapeutics, founded by Craig Beeson PhD and Bärbel Rohrer PhD in Charleston, South Carolina, focuses on developing treatments for neurodegenerative diseases by addressing mitochondrial dysfunction. The company's core mission is to pioneer mitochondrial protective therapeutics, specifically targeting ocular and neurodegenerative conditions. Leveraging the combined expertise of its founders in medicinal chemistry and neuroscience, MitoChem aims to create innovative solutions that improve patient outcomes in these challenging medical fields.

Notable affiliated individuals include Dr. Beeson, a Professor of Drug Discovery and Biomedical Sciences, and Dr. Rohrer, a Professor of Ophthalmology, both at the Medical University of South Carolina. MitoChem has garnered attention for its cutting-edge approach to treating diseases linked to mitochondrial dysfunction, contributing significantly to the field of neurodegenerative research. The startup's impact is marked by its potential to transform therapeutic strategies and offer hope for patients suffering from debilitating conditions.